TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Nov 30, 2021 10:13 JST
Source:
Eisai
Eisai and FCNT Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
Developing solutions such as smartphones equipped with the brain health check tool "NouKNOW"
TOKYO, Nov 30, 2021 - (JCN Newswire) - Eisai Co., Ltd. and FCNT LIMITED announced today that both companies have entered into a business alliance agreement aiming to support people living with dementia and to prevent dementia, through developing solutions for maintaining brain performance. Both companies will construct an ecosystem with the aim of supporting people living with and preventing dementia ("Dementia Ecosystem"), with integrating Eisai's wealth of experience and knowledge including drug creation and disease awareness activities as well as Eisai's solution measures such as digital technology, in the area of dementia, and FCNT's products such as smartphones designed to offer outstanding usability for the elderly as well as FCNT's services including "Raku Raku Community" on SNS targeting such smartphone users. With constructing a "Dementia Ecosystem", both companies aim to contribute to the solution of dementia, which is one of the important social issues in an aging society.
The initiatives planned under the alliance are as follows.
1. The "NouKNOW" will be installed on the "Raku Raku Smartphone"
The "Raku Raku Smartphone F-52B" developed and manufactured by FCNT will be equipped with the digital tool for self-assessment of brain performance (brain health) "NouKNOW" (pronounced "NOH-NOH", non-medical equipment) distributed by Eisai. It is scheduled to be released by NTT DOCOMO, INC. in or after February 2022. This will be the first time that "NouKNOW" is deployed as a function that can be operated on a smartphone. F-52B users will be provided with brain performance checks at no cost by "NouKNOW" up to 4 times a year.
2. Developing solutions for retaining good health and the disease prevention
Eisai and FCNT will develop highly convenient solutions for the prevention of dementia, such as identifying future health concerns and predicting risks, with utilizing FCNT's healthcare information infrastructure to accumulate data available among users, including step count, step speed and heart rate, as well as its management capacity to develop membership services such as "Raku-Raku Community" (2.4 million members as of August 2021. Based on available information by FCNT), an SNS service for seniors with a membership system, in addition to Eisai's know-how based on various data in the area of dementia. Furthermore, the both companies aim to deploy the new solutions developed based on this alliance for corporate customer, including businesses and regional governments, as a packaged solution that combines products and services owned by not only Eisai and FCNT but also other industries and organizations.
Eisai and FCNT will address and resolve the social issue related to dementia, and promote co-creation of value toward realizing a healthy and long-lived society through contributing to the construction of a "Dementia Ecosystem" by combining the strengths of the both companies.
For more information, visit
https://www.eisai.com/news/2021/news202195.html
.
Source: Eisai
Sectors: BioTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
February 06 2026 10:31 JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
January 26 2026 10:37 JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
January 21 2026 15:44 JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
December 04 2025 17:36 JST
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 03 2025 17:19 JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
December 02 2025 23:01 JST
More Press release >>
Latest Press Release
Mitsubishi Motors Launches the All-New Versa Van in the Philippine Market
Feb 06, 2026 13:34 JST
Establishment of the World's First*1 Global Supply Chain to Introduce the Use of Renewable Plastics in Sony's High-Performance Products
Feb 06, 2026 11:50 JST
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
Feb 06, 2026 11:31 JST
Fujitsu Japan and JMDC announce collaboration to build sustainable healthcare system in Japan through enhanced medical data utilization
Feb 06, 2026 11:14 JST
Genesys and Fujitsu Transform AEON Financial Service's Contact Center Operations with Genesys Cloud Delivers Customers an Improved Self-Service Experience Resulting in Higher Completion and Reduced Wait Times
Feb 06, 2026 10:44 JST
TANAKA PRECIOUS METAL TECHNOLOGIES establishes total solutions system for contract manufacturing of various test kits including in vitro diagnostics
Feb 05, 2026 22:00 JST
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
Feb 05, 2026 11:55 JST
Hitachi significantly expands exhibits at the "Hitachi Building Solutions Lab", a research facility for collaborative creation with customers
Feb 05, 2026 11:48 JST
Japantastics Launches Global Curator Platform Bringing Japan Craftsmanship to the World
Feb 04, 2026 22:00 JST
The 55-Point Gap: Measuring What Matters in Automotive Impact
Feb 04, 2026 18:00 JST
Mitsubishi Heavy Industries Announces Large Order Intake, Revenue, and Profit Growth in First Three Quarters, Raises Full-Year Guidance
Feb 04, 2026 17:13 JST
Honda Co-developing Automobile SoC with U.S.-based Mythic to Accelerate Research to Enhance AI Computing Performance and Energy Efficiency
Feb 04, 2026 11:32 JST
DENSO Announces Third Quarter Financial Results
Feb 03, 2026 19:36 JST
FWD Group survey reveals over 70 per cent of Asia's middle-class feel anxiety about financial wellbeing, preventing longer-term planning
Feb 03, 2026 15:13 JST
Fujitsu's Takane LLM successfully piloted in central government agency to streamline public comment operations
Feb 03, 2026 11:14 JST
EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions
Feb 03, 2026 10:00 JST
SGL Golf Launches in U.S. Market to Meet Demand for Autonomous Course Management Solutions
Feb 03, 2026 03:00 JST
Lockheed Martin and Fujitsu to accelerate dual-use technology development
Feb 02, 2026 16:29 JST
Fujitsu introduces biometric authentication service for SMBC Nikko Securities Online Trading
Feb 02, 2026 14:30 JST
JCB Launches Usage Promotion Campaign for Inbound Visitors in Fukuoka's Tenjin Area
Feb 02, 2026 10:00 JST
More Latest Release >>